Cancer Immunotherapy: PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy (Adv. Mater. 22/2018) | Zendy

Zhang Xudong | Zendy; Wang Chao | Zendy; Wang Jinqiang | Zendy; Hu Quanyin | Zendy; Langworthy Benjamin | Zendy; Ye Yanqi | Zendy; Sun Wujin | Zendy; Lin Jing | Zendy; Wang Tianfu | Zendy; Fine Jason | Zendy; Cheng Hao | Zendy; Dotti Gianpietro | Zendy; Huang Peng | Zendy; Gu Zhen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Cancer Immunotherapy: PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy (Adv. Mater. 22/2018)

Author(s) -

Zhang Xudong,

Wang Chao,

Wang Jinqiang,

Hu Quanyin,

Langworthy Benjamin,

Ye Yanqi,

Sun Wujin,

Lin Jing,

Wang Tianfu,

Fine Jason,

Cheng Hao,

Dotti Gianpietro,

Huang Peng,

Gu Zhen

Publication year - 2018

Publication title -

advanced materials

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.707

H-Index - 527

eISSN - 1521-4095

pISSN - 0935-9648

DOI - 10.1002/adma.201870152

Subject(s) - immunotherapy , cancer immunotherapy , cancer , materials science , cancer therapy , cancer cell , blockade , immune system , cancer research , nanotechnology , receptor , immunology , medicine

In article number 1707112 , Peng Huang, Zhen Gu, and co‐workers engineer cellular nanovesicles presenting PD‐1 receptors on their membranes, which enhance antitumor response by disrupting the PD‐1/PD‐L1 immune inhibitory axis. These nanovesicles could also be adapted to carry a variety of therapeutics to achieve synergistic cancer therapy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research